A Randomised, Double-blind, Double-dummy, Placebo-controlled, Forced-titration, Comparison of MICARDIS® HCT (Telmisartan 80 mg / Hydrochlorothiazide 25 mg) Versus DIOVAN® HCT (Valsartan 160 mg / Hydrochlorothiazide 25 mg) Using Seated Trough Cuff Blood Pressure in Patients With Stage 1 and Stage 2 Hypertension

NCT00240448 Phase 4 COMPLETED

The primary objective of this study is to compare the effectiveness of telmisartan 80 mg/hydrochlorothiazide 25 mg \[Micardis HCT\] to valsartan 160 mg/hydrochlorothiazide 25 mg \[Diovan HCT\] and placebo in the treatment of Stage 1 and Stage 2 hypertension.

Details

Lead sponsor	Boehringer Ingelheim
Phase	Phase 4
Status	COMPLETED
Enrolment	1109
Start date	2003-09

Conditions

• Hypertension

Interventions

• telmisartan 80 mg/hydrochlorothiazide 25 mg
• valsartan 160 mg/hydrochlorothiazide 25 mg
• placebo

Primary outcomes

• Change from baseline in mean seated trough cuff diastolic and systolic blood pressure measurements at the end of an 8-week treatment period

Countries

United States